Abiomed (ABMD) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
April 28, 2022 7:00 AM EDTFY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year
DANVERS, Mass.--(BUSINESS WIRE)-- ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022.
Financial summary and operational highlights:
Revenue for the quarter totaled $270 million, an increase of 12% compared to $241 million during the same period of the prior fiscal year. In constant currency*, revenue increased 13% compared to the same period of the prior fiscal year.... More